| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |